– Study Results Highlight Potential Utility of Targeting Mannose 6-Phosphate Pathway to Treat Multiple Lysosomal Storage Disorders – ST. LOUIS, Mo., – February 11, 2022 – M6P Therapeutics (“M6PT” or “the Company”), a privately held life sciences company developing next-generation enzyme replacement and gene therapies for lysosomal storage disorders (LSDs), today announced the presentation of promising preclinical …
Continue readingM6P Therapeutics to Participate in Key Event Highlights at WORLDSymposium™ 2022 and Present Preclinical Data Across Multiple Lysosomal Diseases
– M6P Therapeutics (“M6PT” or “the Company”), a privately held life sciences company Co-founder of M6PT, Dr. Stuart Kornfeld, to receive the 2022 Roscoe O. Brady Award for Innovation and Accomplishment – – Preclinical data across three lysosomal disorders demonstrate the broad potential of the Company’s therapies developed under its novel S1S3 co-expression technology platform …
Continue reading